Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Возможность применения нимесулида у пациентов с поясничной болью
Возможность применения нимесулида у пациентов с поясничной болью
Камчатнов П.Р., Евзельман М.А., Чугунов А.В. Возможность применения нимесулида у пациентов с поясничной болью. Consilium Medicum. 2017; 19 (2.2. Неврология и Ревматология): 52–57.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Рассматриваются вопросы эффективности и безопасности лечения пациентов с синдромом поясничной боли. Приводятся сведения о возможных нежелательных побочных эффектах терапии, причинах и факторах риска их развития. Подробно анализируются сведения о возможности применения препарата нимесулид (Найз®) у пациентов с поясничной болью. Приведены результаты современных исследований, посвященных безопасности его применения, в частности, в отношении желудочно-кишечного тракта, сердечно-сосудистой системы, печени. Делается вывод о целесообразности применения препарата у пациентов с поясничной болью; для минимизации риска развития побочных эффектов следует проводить детальную оценку клинической картины, учет вероятности лекарственных взаимодействий, строго следовать рекомендациям по применению препарата.
Ключевые слова: поясничная боль, нимесулид, Найз, лечение, побочные эффекты.
A conclusion is made about the advisability of using the drug in patients with lumbar pain; To minimize the risk of side effects, a detailed assessment of the clinical picture, taking into account the likelihood of drug interactions, strict adherence to recommendations for the use of the drug should be carried out.
Key words: lumbar pain, nimesulide, Nise, treatment, side effects.
Ключевые слова: поясничная боль, нимесулид, Найз, лечение, побочные эффекты.
________________________________________________
A conclusion is made about the advisability of using the drug in patients with lumbar pain; To minimize the risk of side effects, a detailed assessment of the clinical picture, taking into account the likelihood of drug interactions, strict adherence to recommendations for the use of the drug should be carried out.
Key words: lumbar pain, nimesulide, Nise, treatment, side effects.
Полный текст
Список литературы
1. CDC. National Ambulatory Medical Care Survey: 2010 Summary Tables. Table 9. Accessed March 29, 2016. www.cdc.gov/nchs/data/ahcd/namcs_summary/2010_namcs_web_tables.pdf
2. Davies C, Nitz A, Mattacola C et al. Practice patterns when treating patients with low back pain: a survey of physical therapists. Physiother Theor Pract 2014; 30 (6): 399–408.
3. Vos T, Flaxman A, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163–96.
4. Hoy D, March L, Brooks P et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014; 73: 968–74.
5. Есин Р.Г., Есин О.Р., Ахмадеева Г.Д., Салихова Г.В. Боль в спине. Казань: Казанский полиграфкомбинат, 2010; с. 272. / Esin R.G., Esin O.R., Akhmadeeva G.D., Salikhova G.V. Bol' v spine. Kazan': Kazanskii poligrafkombinat, 2010; s. 272. [in Russian]
6. Koffeman A, Valkhoff V, Celik S et al. High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study. Br J Gen Pract 2014; 64 (621): e191–e198.
7. Brattwall M, Turan I, Jakobsson J. Musculoskeletal pain: prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004–2008 – a retrospective patient record review. J Pain Research 2010; 3: 131–5.
8. Барулин А.Е., Курушина О.В., Пучков А.Е. Комплексное лечение острой неспецифической боли в нижней части спины. Неврология, нейропсихиатрия, психосоматика. 2014; 6 (3): 38–42. DOI: 10.14412/2074-2711-2014-3-38-42 / Barulin A.E., Kurushina O.V., Puchkov A.E. Kompleksnoe lechenie ostroi nespetsificheskoi boli v nizhnei chasti spiny. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2014; 6 (3): 38–42. DOI: 10.14412/2074-2711-2014-3-38-42 [in Russian]
9. Баранцевич Е., Андреев В. Возможности лечения хронической боли при пояснично-крестцовой радикулопатии. Врач. 2012; 11: 13–9. / Barantsevich E., Andreev V. Vozmozhnosti lecheniia khronicheskoi boli pri poiasnichno-kresttsovoi radikulopatii. Vrach. 2012; 11: 13–9. [in Russian]
10. Goldstein J, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf 2015; 7: 31–41.
11. Enthoven W, Roelofs P, Deyo R et al. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev 2016; 2: CD012087.
12. Figueiras A, Estany-Gestal A, Aguirre C et al. EMPHOGEN group. CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study. Pharmacogenet Genom 2016; 26 (2): 66–73.
13. Moodley I. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc J Afr 2008; 19 (2): 102–6.
14. Grosser T, Fries S, Fitzgerald G. Biological basis for the cardiovascular consequences of Cox 2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4–15.
15. Agúndez J, Lucena M, Martínez C et al. Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Exp Opin Drug Metab Toxicol 2011; 7 (7): 817–28.
16. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16 (45): 5651–61.
17. Binning A. Nimesulide in the treatment of postoperative pain: a double-blind, comparative study in patients undergoing arthroscopic knee surgery. Clin J Pain 2007; 23 (7): 565–70.
18. Omololu B, Alonge T, Ogunlade S, Aduroja O. Double blind clinical trial comparing the safety and efficacy of nimesulide (100 mg) and diclofenac in osteoarthrosis of the hip and knee joints. West Afr J Med 2005; 24 (2): 128–33.
19. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine 2000; 25 (12): 1579–85.
20. Ilic K, Sefik-Bukilica M, Jankovic S, Vujasinovic-Stupar N. Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis. Reumatismo 2009; 61 (1): 27–33.
21. Шихкеримов Р.К. Применение нимесулида у пациентов с поясничной болью. Журн. неврологи и психиатрии им. С.С.Корсакова. 2016; 116 (5): 28–32. / Shikhkerimov R.K. Primenenie nimesulida u patsientov s poiasnichnoi bol'iu. Zhurn. nevrologi i psikhiatrii im. S.S.Korsakova. 2016; 116 (5): 28–32. [in Russian]
22. Каратеев А.Е., Алексеева Л.И., Братыгина Е.А., Аширова Т.Б. Оценка частоты развития побочных эффектов при длительном применении нимесулида в реальной клинической практике. РМЖ. 2009; 17 (21): 1466–72. / Karateev A.E., Alekseeva L.I., Bratygina E.A., Ashirova T.B. Otsenka chastoty razvitiia pobochnykh effektov pri dlitel'nom primenenii nimesulida v real'noi klinicheskoi praktike. RMZh. 2009; 17 (21): 1466–72. [in Russian]
23. Castellsague J, Pisa F, Rosolen V et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf 2013; 22 (4): 365–75.
24. Lapi F, Piccinni C, Simonetti M et al. Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study. Intern Emerg Med 2016; 11 (1): 49–59.
25. Donati M, Conforti A, Lenti M еt al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol 2016; 82 (1): 238–48.
26. Rainsford K. Members of the Consensus Report Group on Nimesulide. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006; 22 (6): 1161–70.
27. Gulmez S, Larrey D, Pageaux G et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf 2013; 36 (2): 135–44.
28. Schmeltzer P, Kosinski A, Kleiner D et al. Drug-Induced Liver Injury Network (DILIN). Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int 2016; 36 (4): 603–9.
29. Kress HG, Baltov A, Basiński A et al. Acute pain: a multifaceted challenge – the role of nimesulide. Curr Med Res Opin 2016; 32 (1): 23–36.
30. Franchi S, Heiman F, Visentin E, Sacerdote P. Survey on appropriateness of use of nimesulide in nine European countries. Drug Healthc Patient Saf 2015; 7: 51–5.
31. Kshirsagar N, Bachhav S. Nimesulide controversy: a comparison of EU and Indian scenario. Int J Risk Saf Med 2013; 25 (4): 239–46.
2. Davies C, Nitz A, Mattacola C et al. Practice patterns when treating patients with low back pain: a survey of physical therapists. Physiother Theor Pract 2014; 30 (6): 399–408.
3. Vos T, Flaxman A, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163–96.
4. Hoy D, March L, Brooks P et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014; 73: 968–74.
5. Esin R.G., Esin O.R., Akhmadeeva G.D., Salikhova G.V. Bol' v spine. Kazan': Kazanskii poligrafkombinat, 2010; s. 272. [in Russian]
6. Koffeman A, Valkhoff V, Celik S et al. High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study. Br J Gen Pract 2014; 64 (621): e191–e198.
7. Brattwall M, Turan I, Jakobsson J. Musculoskeletal pain: prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004–2008 – a retrospective patient record review. J Pain Research 2010; 3: 131–5.
8. Barulin A.E., Kurushina O.V., Puchkov A.E. Kompleksnoe lechenie ostroi nespetsificheskoi boli v nizhnei chasti spiny. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2014; 6 (3): 38–42. DOI: 10.14412/2074-2711-2014-3-38-42 [in Russian]
9. Barantsevich E., Andreev V. Vozmozhnosti lecheniia khronicheskoi boli pri poiasnichno-kresttsovoi radikulopatii. Vrach. 2012; 11: 13–9. [in Russian]
10. Goldstein J, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf 2015; 7: 31–41.
11. Enthoven W, Roelofs P, Deyo R et al. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev 2016; 2: CD012087.
12. Figueiras A, Estany-Gestal A, Aguirre C et al. EMPHOGEN group. CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study. Pharmacogenet Genom 2016; 26 (2): 66–73.
13. Moodley I. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc J Afr 2008; 19 (2): 102–6.
14. Grosser T, Fries S, Fitzgerald G. Biological basis for the cardiovascular consequences of Cox 2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4–15.
15. Agúndez J, Lucena M, Martínez C et al. Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Exp Opin Drug Metab Toxicol 2011; 7 (7): 817–28.
16. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16 (45): 5651–61.
17. Binning A. Nimesulide in the treatment of postoperative pain: a double-blind, comparative study in patients undergoing arthroscopic knee surgery. Clin J Pain 2007; 23 (7): 565–70.
18. Omololu B, Alonge T, Ogunlade S, Aduroja O. Double blind clinical trial comparing the safety and efficacy of nimesulide (100 mg) and diclofenac in osteoarthrosis of the hip and knee joints. West Afr J Med 2005; 24 (2): 128–33.
19. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine 2000; 25 (12): 1579–85.
20. Ilic K, Sefik-Bukilica M, Jankovic S, Vujasinovic-Stupar N. Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis. Reumatismo 2009; 61 (1): 27–33.
21. Shikhkerimov R.K. Primenenie nimesulida u patsientov s poiasnichnoi bol'iu. Zhurn. nevrologi i psikhiatrii im. S.S.Korsakova. 2016; 116 (5): 28–32. [in Russian]
22. Karateev A.E., Alekseeva L.I., Bratygina E.A., Ashirova T.B. Otsenka chastoty razvitiia pobochnykh effektov pri dlitel'nom primenenii nimesulida v real'noi klinicheskoi praktike. RMZh. 2009; 17 (21): 1466–72. [in Russian]
23. Castellsague J, Pisa F, Rosolen V et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf 2013; 22 (4): 365–75.
24. Lapi F, Piccinni C, Simonetti M et al. Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study. Intern Emerg Med 2016; 11 (1): 49–59.
25. Donati M, Conforti A, Lenti M еt al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol 2016; 82 (1): 238–48.
26. Rainsford K. Members of the Consensus Report Group on Nimesulide. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006; 22 (6): 1161–70.
27. Gulmez S, Larrey D, Pageaux G et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf 2013; 36 (2): 135–44.
28. Schmeltzer P, Kosinski A, Kleiner D et al. Drug-Induced Liver Injury Network (DILIN). Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int 2016; 36 (4): 603–9.
29. Kress HG, Baltov A, Basiński A et al. Acute pain: a multifaceted challenge – the role of nimesulide. Curr Med Res Opin 2016; 32 (1): 23–36.
30. Franchi S, Heiman F, Visentin E, Sacerdote P. Survey on appropriateness of use of nimesulide in nine European countries. Drug Healthc Patient Saf 2015; 7: 51–5.
31. Kshirsagar N, Bachhav S. Nimesulide controversy: a comparison of EU and Indian scenario. Int J Risk Saf Med 2013; 25 (4): 239–46.
2. Davies C, Nitz A, Mattacola C et al. Practice patterns when treating patients with low back pain: a survey of physical therapists. Physiother Theor Pract 2014; 30 (6): 399–408.
3. Vos T, Flaxman A, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163–96.
4. Hoy D, March L, Brooks P et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014; 73: 968–74.
5. Есин Р.Г., Есин О.Р., Ахмадеева Г.Д., Салихова Г.В. Боль в спине. Казань: Казанский полиграфкомбинат, 2010; с. 272. / Esin R.G., Esin O.R., Akhmadeeva G.D., Salikhova G.V. Bol' v spine. Kazan': Kazanskii poligrafkombinat, 2010; s. 272. [in Russian]
6. Koffeman A, Valkhoff V, Celik S et al. High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study. Br J Gen Pract 2014; 64 (621): e191–e198.
7. Brattwall M, Turan I, Jakobsson J. Musculoskeletal pain: prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004–2008 – a retrospective patient record review. J Pain Research 2010; 3: 131–5.
8. Барулин А.Е., Курушина О.В., Пучков А.Е. Комплексное лечение острой неспецифической боли в нижней части спины. Неврология, нейропсихиатрия, психосоматика. 2014; 6 (3): 38–42. DOI: 10.14412/2074-2711-2014-3-38-42 / Barulin A.E., Kurushina O.V., Puchkov A.E. Kompleksnoe lechenie ostroi nespetsificheskoi boli v nizhnei chasti spiny. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2014; 6 (3): 38–42. DOI: 10.14412/2074-2711-2014-3-38-42 [in Russian]
9. Баранцевич Е., Андреев В. Возможности лечения хронической боли при пояснично-крестцовой радикулопатии. Врач. 2012; 11: 13–9. / Barantsevich E., Andreev V. Vozmozhnosti lecheniia khronicheskoi boli pri poiasnichno-kresttsovoi radikulopatii. Vrach. 2012; 11: 13–9. [in Russian]
10. Goldstein J, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf 2015; 7: 31–41.
11. Enthoven W, Roelofs P, Deyo R et al. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev 2016; 2: CD012087.
12. Figueiras A, Estany-Gestal A, Aguirre C et al. EMPHOGEN group. CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study. Pharmacogenet Genom 2016; 26 (2): 66–73.
13. Moodley I. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc J Afr 2008; 19 (2): 102–6.
14. Grosser T, Fries S, Fitzgerald G. Biological basis for the cardiovascular consequences of Cox 2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4–15.
15. Agúndez J, Lucena M, Martínez C et al. Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Exp Opin Drug Metab Toxicol 2011; 7 (7): 817–28.
16. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16 (45): 5651–61.
17. Binning A. Nimesulide in the treatment of postoperative pain: a double-blind, comparative study in patients undergoing arthroscopic knee surgery. Clin J Pain 2007; 23 (7): 565–70.
18. Omololu B, Alonge T, Ogunlade S, Aduroja O. Double blind clinical trial comparing the safety and efficacy of nimesulide (100 mg) and diclofenac in osteoarthrosis of the hip and knee joints. West Afr J Med 2005; 24 (2): 128–33.
19. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine 2000; 25 (12): 1579–85.
20. Ilic K, Sefik-Bukilica M, Jankovic S, Vujasinovic-Stupar N. Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis. Reumatismo 2009; 61 (1): 27–33.
21. Шихкеримов Р.К. Применение нимесулида у пациентов с поясничной болью. Журн. неврологи и психиатрии им. С.С.Корсакова. 2016; 116 (5): 28–32. / Shikhkerimov R.K. Primenenie nimesulida u patsientov s poiasnichnoi bol'iu. Zhurn. nevrologi i psikhiatrii im. S.S.Korsakova. 2016; 116 (5): 28–32. [in Russian]
22. Каратеев А.Е., Алексеева Л.И., Братыгина Е.А., Аширова Т.Б. Оценка частоты развития побочных эффектов при длительном применении нимесулида в реальной клинической практике. РМЖ. 2009; 17 (21): 1466–72. / Karateev A.E., Alekseeva L.I., Bratygina E.A., Ashirova T.B. Otsenka chastoty razvitiia pobochnykh effektov pri dlitel'nom primenenii nimesulida v real'noi klinicheskoi praktike. RMZh. 2009; 17 (21): 1466–72. [in Russian]
23. Castellsague J, Pisa F, Rosolen V et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf 2013; 22 (4): 365–75.
24. Lapi F, Piccinni C, Simonetti M et al. Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study. Intern Emerg Med 2016; 11 (1): 49–59.
25. Donati M, Conforti A, Lenti M еt al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol 2016; 82 (1): 238–48.
26. Rainsford K. Members of the Consensus Report Group on Nimesulide. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006; 22 (6): 1161–70.
27. Gulmez S, Larrey D, Pageaux G et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf 2013; 36 (2): 135–44.
28. Schmeltzer P, Kosinski A, Kleiner D et al. Drug-Induced Liver Injury Network (DILIN). Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int 2016; 36 (4): 603–9.
29. Kress HG, Baltov A, Basiński A et al. Acute pain: a multifaceted challenge – the role of nimesulide. Curr Med Res Opin 2016; 32 (1): 23–36.
30. Franchi S, Heiman F, Visentin E, Sacerdote P. Survey on appropriateness of use of nimesulide in nine European countries. Drug Healthc Patient Saf 2015; 7: 51–5.
31. Kshirsagar N, Bachhav S. Nimesulide controversy: a comparison of EU and Indian scenario. Int J Risk Saf Med 2013; 25 (4): 239–46.
________________________________________________
2. Davies C, Nitz A, Mattacola C et al. Practice patterns when treating patients with low back pain: a survey of physical therapists. Physiother Theor Pract 2014; 30 (6): 399–408.
3. Vos T, Flaxman A, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163–96.
4. Hoy D, March L, Brooks P et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014; 73: 968–74.
5. Esin R.G., Esin O.R., Akhmadeeva G.D., Salikhova G.V. Bol' v spine. Kazan': Kazanskii poligrafkombinat, 2010; s. 272. [in Russian]
6. Koffeman A, Valkhoff V, Celik S et al. High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study. Br J Gen Pract 2014; 64 (621): e191–e198.
7. Brattwall M, Turan I, Jakobsson J. Musculoskeletal pain: prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004–2008 – a retrospective patient record review. J Pain Research 2010; 3: 131–5.
8. Barulin A.E., Kurushina O.V., Puchkov A.E. Kompleksnoe lechenie ostroi nespetsificheskoi boli v nizhnei chasti spiny. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2014; 6 (3): 38–42. DOI: 10.14412/2074-2711-2014-3-38-42 [in Russian]
9. Barantsevich E., Andreev V. Vozmozhnosti lecheniia khronicheskoi boli pri poiasnichno-kresttsovoi radikulopatii. Vrach. 2012; 11: 13–9. [in Russian]
10. Goldstein J, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf 2015; 7: 31–41.
11. Enthoven W, Roelofs P, Deyo R et al. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev 2016; 2: CD012087.
12. Figueiras A, Estany-Gestal A, Aguirre C et al. EMPHOGEN group. CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study. Pharmacogenet Genom 2016; 26 (2): 66–73.
13. Moodley I. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc J Afr 2008; 19 (2): 102–6.
14. Grosser T, Fries S, Fitzgerald G. Biological basis for the cardiovascular consequences of Cox 2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4–15.
15. Agúndez J, Lucena M, Martínez C et al. Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Exp Opin Drug Metab Toxicol 2011; 7 (7): 817–28.
16. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16 (45): 5651–61.
17. Binning A. Nimesulide in the treatment of postoperative pain: a double-blind, comparative study in patients undergoing arthroscopic knee surgery. Clin J Pain 2007; 23 (7): 565–70.
18. Omololu B, Alonge T, Ogunlade S, Aduroja O. Double blind clinical trial comparing the safety and efficacy of nimesulide (100 mg) and diclofenac in osteoarthrosis of the hip and knee joints. West Afr J Med 2005; 24 (2): 128–33.
19. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine 2000; 25 (12): 1579–85.
20. Ilic K, Sefik-Bukilica M, Jankovic S, Vujasinovic-Stupar N. Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis. Reumatismo 2009; 61 (1): 27–33.
21. Shikhkerimov R.K. Primenenie nimesulida u patsientov s poiasnichnoi bol'iu. Zhurn. nevrologi i psikhiatrii im. S.S.Korsakova. 2016; 116 (5): 28–32. [in Russian]
22. Karateev A.E., Alekseeva L.I., Bratygina E.A., Ashirova T.B. Otsenka chastoty razvitiia pobochnykh effektov pri dlitel'nom primenenii nimesulida v real'noi klinicheskoi praktike. RMZh. 2009; 17 (21): 1466–72. [in Russian]
23. Castellsague J, Pisa F, Rosolen V et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf 2013; 22 (4): 365–75.
24. Lapi F, Piccinni C, Simonetti M et al. Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study. Intern Emerg Med 2016; 11 (1): 49–59.
25. Donati M, Conforti A, Lenti M еt al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol 2016; 82 (1): 238–48.
26. Rainsford K. Members of the Consensus Report Group on Nimesulide. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006; 22 (6): 1161–70.
27. Gulmez S, Larrey D, Pageaux G et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf 2013; 36 (2): 135–44.
28. Schmeltzer P, Kosinski A, Kleiner D et al. Drug-Induced Liver Injury Network (DILIN). Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int 2016; 36 (4): 603–9.
29. Kress HG, Baltov A, Basiński A et al. Acute pain: a multifaceted challenge – the role of nimesulide. Curr Med Res Opin 2016; 32 (1): 23–36.
30. Franchi S, Heiman F, Visentin E, Sacerdote P. Survey on appropriateness of use of nimesulide in nine European countries. Drug Healthc Patient Saf 2015; 7: 51–5.
31. Kshirsagar N, Bachhav S. Nimesulide controversy: a comparison of EU and Indian scenario. Int J Risk Saf Med 2013; 25 (4): 239–46.
Авторы
П.Р.Камчатнов*1, М.А.Евзельман2, А.В.Чугунов1
1 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
2 ФГБОУ ВО «Орловский государственный университет им. И.С.Тургенева». 302026, Россия, Орел, ул. Комсомольская, д. 95
*pavkam7@gmail.com
1 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
2 I.S.Turgenev Orel State University. 302026, Russian Federation, Orel, ul. Komsomolskaia, d. 95
*pavkam7@gmail.com
1 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
2 ФГБОУ ВО «Орловский государственный университет им. И.С.Тургенева». 302026, Россия, Орел, ул. Комсомольская, д. 95
*pavkam7@gmail.com
________________________________________________
1 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
2 I.S.Turgenev Orel State University. 302026, Russian Federation, Orel, ul. Komsomolskaia, d. 95
*pavkam7@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.